Pancreatic carcinoma surveillance in patients with familial melanoma

Archives of Dermatology

Volumn 139, Issue 8, 2003, Pages 1019-1025

  Parker, Jana Foley ^d   Florell, Scott R ^a   Alexander, April ^a   DiSario, James A ^b   Shami, Paul J ^c,e   Leachman, Sancy A ^a  

^a UNIVERSITY OF UTAH   (United States)

^b Division of Gastroenterology   (United States)

^c Division of Hematology/Oncology   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 2; GENOMIC DNA;

ADULT; ARTICLE; CASE REPORT; DNA SEQUENCE; FAMILIAL CANCER; FAMILY HISTORY; GENE MUTATION; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; PANCREAS CARCINOMA; PEDIGREE ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SKIN CANCER;

ADENOCARCINOMA; ADULT; CYCLIN-DEPENDENT KINASE INHIBITOR P16; HUMANS; MALE; MELANOMA; MIDDLE AGED; MUTATION; PANCREATIC NEOPLASMS; PEDIGREE; POPULATION SURVEILLANCE; RISK FACTORS; SKIN NEOPLASMS;

EID: 0042522711     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.139.8.1019     Document Type: Article

References (70)

1. Goldstein AM, Tucker MA. Genetic epidemiology of cutaneous melanoma: a global perspective. Arch Dermatol. 2001;137:1493-1496.
2. Piepkorn MW. Genetic basis of susceptibility to melanoma. J Am Acad Dermatol. 1994;31:1022-1039.
3. Della Ragione F, Russo G, Oliva A, et al. 5′-Deoxy-5′ methylthioadenosine phosphorylase and p16INK4 deficiency in multiple tumor cell lines. Oncogene. 1995;10:827-833.
4. Goldstein AM, Dracopoli NC, Engelstein M, Frase MC, Clark WH, Tucker MA. Linkage of cutaneous malignant melanoma/dysplastic nevi to chromosome 9p, and evidence for genetic heterogeneity. Am J Hum Genet. 1994;54:489-496.
5. Gruis NA, Sandkuijl LA, van der Velden PA, Bergman W, Frants RR. CDKN2 explains part of the clinical phenotype in Dutch familial atypical multiple-mole melanoma (FAMMM) syndrome families. Melanoma Res. 1995;5:169-177.
6. Harland M, Meloni R, Gruis N, et al. Germline mutations of the CDKN2A gene in UK melanoma families. Hum Mol. Genet 1997;6:2061-2067.
7. Holland EA, Beaton SC, Becker TM, et al. Analysis of the p16 gene, CDKN2, in 17 Australian melanoma kindreds. Oncogene. 1995;11:2289-2294.
8. Hussussian CJ, Struewing JP, Goldstein AM, et al. Germline p16 mutations in familial melanoma. Nat Genet. 1994;8:15-21.
9. Ranade K, Hussussian CJ, Sikorski RS, et al. Mutations associated with familial melanoma impair p16INK4 function. Nat Genet. 1995;10:114-116.
10. Walker GJ, Hussussian CJ, Flores JF, et al. Mutations of the CDKN2/p16INK4 gene in Australian melanoma kindreds. Hum Mol Genet. 1995;4:1845-1852.
11. Lal G, Liu L, Hogg D, Lassam NJ, Redston MS, Gallinger S. Patients with both pancreatic adenocarcinoma and melanoma may harbor germline CDKN2A mutations. Genes Chromosomes Cancer. 2000;27:358-361.
12. Piepkorn M. Melanoma genetics: an update with focus on the CDKN2A(p16)/ARF tumor suppressors. J Am Acad Dermatol. 2000;42:705-722.
13. Ruas M, Peters G. The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta. 1998;1378:F115-F177.
14. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 1993;366:704-707.
15. Clark WH, Reimer RR, Greene M, Ainsworth AM, Mastrangelo MJ. Origin of familial malignant melanomas from heritable melanocytic lesions: "the B-K mole syndrome." Arch Dermatol. 1978;114:732-738.
16. Newton-Bishop JA, Bataille V, Pinney E, Bishop DT. Family studies in melanoma: identification of the atypical mole syndrome (AMS) phenotype. Melanoma Res. 1994;4:199-206.
17. Vasen HFA, Gruis NA, Frantis RR, van der Velden PA, Hille ETM, Berman W. Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). Int J Cancer. 2000;87:809-811.
18. Bergman W, Watson P, de Jong J, Lynch HT, Fusaro RM. Systemic cancer and the FAMMM syndrome. Br J Cancer. 1990;61:932-936.
19. Bergman W, Gruis N. Familial melanoma and pancreatic cancer [letter]. N Engl J Med. 1996;334:471-472.
20. Borg A, Sandberg T, Nilsson K, et al. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J Natl Cancer Inst. 2000;92:1260-1266.
21. Ghiorzo P, Ciotti P, Martelli M, et al. Characterization of ligurian melanoma families and risk of occurrence of other neoplasia. Int J Cancer. 1999;83:441-448.
22. Goldstein AM, Fraser MC, Struewing JP, et al. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med. 1995;333:970-974.
23. Hille ETM, van Duijn E, Gruis NA, Rosendaal FR, Bergman W, Vandenbroucke JP. Excess cancer mortality in six Dutch pedigrees with the familial atypical multiple mole-melanoma syndrome from 1830 to 1994. J Invest Dermatol. 1998;110:788-792.
24. Lal G, Liu G, Schmocker G, et al. Inherited predisposition to pancreatic adenocarcinoma. Cancer Res. 2000;60:409-416.
25. Schutte M, Hruban RH, Geradts J, et al. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res. 1997;57:3126-3130.
26. Whelan AJ, Bartsch D, Goodfellow PJ. Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. N Engl J Med. 1995;333:975-977.
27. Lynch HT, Brand RB, Hogg D, et al. Phenotypic variation in eight extended CKDN2A germline mutation familial atypical mole melanoma-pancreatic carcinoma-prone families. Cancer. 2002;94:84-96.
28. American Gastroenterological Association medical position statement. Gastroenterology. 1999;117:1463-1484.
29. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics 2002. CA Cancer J Clin. 2002;52:23-47.
30. Hruban RH, Canto MI, Yeo CJ. Prevention of pancreatic cancer and strategies for management of familial pancreatic cancer. Dig Dis. 2001;19:76-84.
31. Kerber RA. Method for calculating risk associated with family history of a disease. Genet Epidemiol. 1995;12:291-301.
32. Chu P, Wu E, Weiss L. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod Pathol. 2000;13:962-972.
33. Ichihara T, Nomoto S, Takeda S, et al. Clinical usefulness of the immunostaining of the tumor markers in pancreatic cancer. Hepatogastroenterology. 2001;48:939-943.
34. Tot T. Adenocarcinomas metastatic to the liver. Cancer. 1999;85:171-177.
35. Tot T. The value of cytokeratins 20 and 7 in discriminating metastatic adenocarcinomas from pleural mesotheliomas. Cancer. 2001;92:2727-2732.
36. Florell SR, Coffin CM, Holden JA, et al. Preservation of RNA for functional genomic studies: a multidisciplinary tumor bank protocol. Mod Pathol. 2001;14:116-128.
37. Florell SR, Zone JJ, Gerwels JW. Basal cell carcinomas are populated by melanocytes and Langerhans cells. Am J Dermatopathol. 2001;23:24-28.
38. Bishop DT, Demenais F, Goldstein A, et al. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst. 2002;94:894-903.
39. Newton-Bishop JA, Wachsmuth RC, Harland M, et al. Genotype/phenotype and penetrance studies in melanoma families with germline CDKN2A mutations. J Invest Dermatol. 2000;114:28-33.
40. Brand RE. The diagnosis of pancreatic cancer. Cancer J. 2001;7:287-297.
41. Brentnall TA. Cancer surveillance of patients from familial pancreatic cancer kindreds. Med Clin North Am. 2000;84:707-718.
42. Brentnall TA, Bronner MP, Byrd DR, Haggitt RC, Kimmey MB. Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann Intern Med. 1999;131:247-255.
43. Bullock GJ, Green JL, Baron PL. Impact of p16 expression on surgical management of malignant melanoma and pancreatic carcinoma. Am J Surg. 1999;177:15-18.
44. Brand RE, Matamoros A. Imaging techniques in the evaluation of adenocarcinoma of the pancreas. Dig Dis. 1998;16:242-252.
45. Niederau C, Grendell JH. Diagnosis of pancreatic carcinoma: imaging techniques and tumor markers. Pancreas. 1992;7:66-86.
46. Antillon MR, Chang KJ. Endoscopic and endosonography guided fine-needle aspiration. Gastrointest Endosc Clin N Am. 2000;10:619-636.
47. Masci E, Toti G, Mariani S, et al. Complications of diagnostic and therapeutic ERCP: a prospective multicenter study. Am J Gastroenterol. 2001;96:417-423.
48. Brennan MF. Quadrennial review: pancreatic cancer. J Gastroenterol Hepatol. 2000;15:G13-G16.
49. Brown RW, Brozo Campagna L, Dunn JK, Cagle PT. Immunohistochemical identification of tumor markers in metastatic adenocarcinoma: a diagnostic adjunct in the determination of primary site. Am J Clin Pathol. 1997;107:12-19.
50. Steinberg W. The clinical utiiity of the CA 19-9 tumor-associated antigen. Am J Gastroenterol. 1990;85:350-355.
51. Cubilla AL, Fitzgerald PJ. Morphological lesions associated with human primary invasive nonendocrine pancreas cancer. Cancer Res. 1976;36:2690-2698.
52. Furukawa T, Ryoji C, Kobari M, Matsuno S, Nagura H, Takahashi T. Varying grades of epithelial atypia in the pancreatic ducts of humans. Arch Pathol Lab Med. 1994;118:227-234.
53. Hruban RH, Goggins M, Parsons J, Kern SE. Progression model for pancreatic cancer. Clin Cancer Res. 2000;6:2969-2972.
54. Vogelstein B, Gearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319:525-532.
55. Klimstra D, Longnecker D. K-ras mutations in pancreatic ductal proliferative lesions. Am J Pathol. 1994;145:1547-1548.
56. Brat DJ, Lillemoe KD, Yeo CJ, Warfield PB, Hruban RH. Progression of pancreatic intraductal neoplasias to infiltrating adenocarcinoma of the pancreas. Am J Surg Pathol. 1998;22:163-169.
57. Brockie E, Anand A, Albores-Saavedra J. Progression of atypical ductal hyperplasia/carcinoma in situ of the pancreas to invasive adenocarcinoma. Ann Diagn Pathol. 1998;2:286-292.
58. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell. 1988;53:549-554.
59. Manu M, Buckels J, Bramhall S. Molecular technology and pancreatic cancer. Br J Surg. 2000;87:840-853.
60. Caldas C, Hahn SA, Hruban RH, et al. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res. 1994;54:3568-3573.
61. Mulcahy H, Anker P, Lyautey J, et al. K-ras mutations in the plasma of pancreatic patients. Clin Cancer Res. 1998;4:271-275.
62. Mulcahy H, Farthing MJG. Diagnosis of pancreatico-biliary malignancy: detection of gene mutations in plasma and stool. Ann Oncol. 1999;10(suppl 4):114-117.
63. Nakaizumi A, Uehara H, Takenaka A, et al. Diagnosis of pancreatic cancer by cytology and measurement of oncogene and tumor markers in pure pancreatic juice aspirated by endoscopy. Hepatogastroenterology. 1999;46:31-37.
64. Tada M, Mata M, Kawai S, et al. Detection of ras gene mutations in pancreatic juice and peripheral blood of patients with pancreatic adenocarcinoma. Cancer Res. 1993;53:2472-2474.
65. Wakabayashi T, Sawabu N, Watanabe H, Morimoto H, Sugioka G, Takita Y. Case reports. Am J Gastroenterol. 1996;91:1848-1851.
66. Watanabe H, Sawabu N, Ohta H, et al. Identification of K-ras oncogene mutations in the pure pancreatic juice of patients with ductal pancreatic cancers. Jpn J Cancer Res. 1993;84:961-965.
67. Yamada T, Nakamori S, Ohzato H, et al. Circulating DNA K-ras mutation in pancreatic adenocarcinoma. Clin Cancer Res. 1998;4:1527-1532.
68. Caldas C. Biliopancreatic malignancy. Ann Oncol. 1999;10(suppl 4):153-156.
69. Hiyama E, Kodama T, Shinbara K, et al. Telomerase activity is detected in pancreatic cancer but not in benign tumors. Cancer Res. 1997;57:326-331.
70. Uehara H, Nakaizumi A, Tatsuta M, et al. Diagnosis of pancreatic cancer by detecting telomerase activity in pancreatic juice: comparison with K-ras mutations. Am J Gastroenterol. 1999;94:2513-2518.